Exhibit 99.1 NEWS RELEASE Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update XEN1101 Phase 3 epilepsy program continues to progress with X-TOLE2 and X-TOLE3 in focal onset seizures and X-ACKT in primary generalized tonic-clonic seizures; completion of patient enrollment in X-TOLE2 expected in late 2024 to early 2025 Planned "end-of-Phase 2" meeting with the FDA in April to support the initiation of XEN1101 Phase 3 program in major depressive disor ...

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q3 2023 Results Conference Call November 8, 2023 4:30 PM ET Company Participants Sherry Aulin - Chief Financial Officer Ian Mortimer - President and Chief Executive Officer Chris Kenney - Chief Medical Officer Chris Von Seggern - Chief Commercial Officer Conference Call Participants Paul Matteis - Stifel Brian Abrahams - RBC Capital Markets Tessa Romero - JPMorgan Andrew Tsai - Jefferies Paul Choi - Goldman Sachs Joseph Thome - TD Cowen Danielle Brill - Raymond James ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-36687 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in its Charter) Canada 98-066 ...

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Sherry Aulin - CFO Ian Mortimer - President and CEO Dr. Chris Kenney - CMO Dr. Chris Von Seggern - Chief Commercial Officer Conference Call Participants Tessa Romero - J.P. Morgan Paul Matteis - Stifel Brian Abrahams - RBC Capital Markets Andrew Tsai - Jefferies Paul Choi - Goldman Sachs Joseph Thome - TD Cowen Danielle Brill - Raymond James Laura Chico - Wedbush Securities Mohit Bansal - ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-36687 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in its Charter) (State or other ju ...

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q1 2023 Results Conference Call May 9, 2023 4:30 PM ET Company Participants Sherry Aulin - CFO Ian Mortimer - President and CEO Dr. Chris Kenney - CMO Dr. Chris Von Seggern - Chief Commercial Officer Conference Call Participants Paul Matteis - Stifel Brian Abrahams - RBC Capital Markets Tessa Romero - J.P. Morgan Andrew Tsai - Jefferies Joseph Thome - TD Cowen Rudy Li - SVB Danielle Brill - Raymond James Laura Chico - Wedbush Securities Elaine Kim - Cantor Fitzgerald ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-36687 XENON PHARMACEUTICALS INC. (Exact name of Registrant as Specified in its Charter) Canada 98-0661854 ...

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q4 2022 Earnings Conference Call March 1, 2023 4:30 PM ET Company Participants Sherry Aulin - CFO Ian Mortimer - President and CEO Chris Kenney - CMO Chris Von Seggern - CCO Conference Call Participants Brian Abrahams - RBC Capital Markets Tessa Romero - JPMorgan Paul Choi - Goldman Sachs Joseph Thome - TD Cowen Andrew Tsai - Jefferies Rudy Li - SVB Securities Laura Chico - Wedbush Rohit Bhasin - Needham & Company Operator Ladies and gentlemen, thank you for standing ...

Financial Performance - The company incurred net losses of $125.4 million, $78.9 million, and $28.8 million for the years ended December 31, 2022, 2021, and 2020, respectively, with an accumulated deficit of $482.7 million as of December 31, 2022[165]. - The company expects to incur significant expenses and increasing operating losses for the foreseeable future due to ongoing research and development activities[166]. - The company anticipates that its existing cash and cash equivalents will enable it to fund operating expenses for at least the next 12 months[171]. - The company may need to raise additional funding, which may not be available on acceptable terms, potentially delaying or terminating product development programs[169]. - The company had Canadian federal net operating loss carryforwards totaling $338.0 million as of December 31, 2022, which will begin to expire in 2026[212]. - The company also had Canadian federal investment tax credit carryforwards of $27.3 million and provincial investment tax credit carryforwards of $8.4 million, which will begin to expire in 2023[212]. Product Development and Commercialization - The company does not generate any revenue from product sales and may never become profitable, as successful commercialization depends on completing development and obtaining regulatory approvals[167]. - The company has no marketed proprietary products and has not completed clinical development beyond Phase 2, complicating its ability to assess future product commercialization[184]. - The company has built a product development pipeline through internal research and acquisitions, with notable candidates like XEN901, now known as NBI-921352, licensed to Neurocrine Biosciences[186]. - The company is heavily investing in the development of its lead product candidate, XEN1101, for the treatment of epilepsy, with no products currently approved for commercial sale[224]. - Successful completion of the XEN1101 Phase 3 program is critical for future business success, with various risks associated with clinical development and regulatory approval[224]. - The company faces challenges in patient enrollment for clinical trials, particularly for ultra-orphan and niche indications, which may delay or prevent clinical trials[239]. - The company must demonstrate that its product candidates are both safe and effective through lengthy and expensive clinical trials before obtaining regulatory approvals[236]. - The company acknowledges that the results of pre-clinical studies may not predict outcomes in later-stage clinical trials, which could lead to unexpected difficulties in obtaining regulatory approval[230]. - The company may incur unexpected costs or delays in the development and commercialization of product candidates due to regulatory approval requirements[244]. Regulatory and Compliance Risks - The company is subject to extensive laws and regulations in the healthcare industry, which could lead to significant compliance costs and potential liabilities[192]. - The company may face significant civil, criminal, and administrative penalties if found in violation of healthcare laws and regulations, which could adversely affect its business[220]. - The company is subject to various healthcare laws, including the federal Anti-Kickback Statute and the federal False Claims Act, which could expose it to legal risks[219]. - The regulatory approval process is lengthy and unpredictable, with potential for significant delays in obtaining marketing approval[257]. - Compliance with changing regulatory requirements can result in increased costs and delays in clinical development plans[262]. - The company may face challenges in demonstrating the safety and efficacy of product candidates to regulatory authorities, impacting approval chances[261]. Market and Competitive Landscape - The company faces substantial competition in the biotechnology and pharmaceutical markets, which may impact its ability to successfully develop and commercialize products[179]. - The company may allocate limited resources to specific product candidates, potentially missing out on more profitable opportunities[173]. - The company’s product candidates targeting rare and ultra-rare disorders may face difficulties in identifying and accessing the limited patient populations, impacting profitability[290]. - Coverage and reimbursement from government programs and private insurers are uncertain, which could adversely affect the commercialization of approved products[292]. - The company must navigate varying price control mechanisms in international markets, which may restrict pricing and reimbursement levels compared to the U.S.[296]. Operational and Growth Challenges - The company may encounter difficulties in managing growth, which could result in operational errors and loss of business opportunities[195]. - The company is highly dependent on its executive officers, and the loss of key personnel could materially delay the development of product candidates[189]. - The company plans to hire additional personnel to expand clinical development activities and commercial capabilities, facing competition for skilled individuals in the pharmaceutical and biotechnology sectors[190]. - The company faces risks associated with evolving global laws and regulations related to privacy and data protection, which may increase compliance costs[196]. - The COVID-19 pandemic has the potential to disrupt the company's supply chain and clinical trials, affecting its business operations[204]. Intellectual Property Risks - The company faces challenges in maintaining adequate patent protection, which is crucial for commercial success[331]. - Intellectual property rights may not provide competitive advantages due to limitations and potential legal challenges[335]. - The company may face claims of patent infringement from third parties, leading to costly litigation and potential damage awards[348]. - Future intellectual property litigation could limit research and development activities and commercialization of products[354]. - The company may need to seek licenses from third parties to avoid patent claims, which could be costly and not available on acceptable terms[355]. Collaboration and Dependency Risks - The company is dependent on collaborators, such as Neurocrine Biosciences, for the research, development, and commercialization of product candidates, which introduces significant uncertainty[305]. - The success of the collaboration with Neurocrine Biosciences for NBI-921352 is largely beyond the company's control, impacting potential financial returns[309]. - The company faces risks related to potential termination of collaboration agreements, which could require it to assume responsibilities and costs for ongoing clinical trials[312]. Manufacturing and Supply Chain Risks - The company relies on third parties for the manufacture and supply of active pharmaceutical ingredients and final drug products, increasing the risk of supply issues[317]. - Manufacturing biopharmaceutical products is complex and requires significant expertise and capital investment, with potential delays in clinical trials due to manufacturing issues[318]. - The company does not enter into long-term supply agreements with manufacturers, which may adversely affect the ability to complete product development[320]. - Compliance with cGMP regulations is mandatory, and any failure could lead to delays in regulatory approval for product candidates[321].

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q3 2022 Results Conference Call November 8, 2022 4:30 PM ET Company Participants Sherry Aulin - Chief Financial Officer Ian Mortimer - President and Chief Executive Officer Chris Kenney - Chief Medical Officer Chris Von Seggern - Chief Commercial Officer Conference Call Participants Paul Matteis - Stifel Andrew Tsai - Jefferies Tessa Romero - JP Morgan Brian Abrahams - RBC Capital Markets Madhumita Yennawar - SVB Securities Laura Chico - Wedbush Yatin Suneja - Guggen ...